Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.
Millions of people worldwide suffer from neuropathic pain as a result of damage to or dysfunction of the nervous system under various disease conditions. Development of effective therapeutic strategies requires a better understanding of molecular and cellular mechanisms underlying the pathogenesis of neuropathic pain. It has been increasingly recognized that spinal cord glial cells such as microglia and astrocytes play a critical role in the induction and maintenance of neuropathic pain by releasing powerful neuromodulators such as proinflammatory cytokines and chemokines. Recent evidence reveals chemokines as new players in pain control. In this article, we review evidence for chemokine modulation of pain via neuronal-glial interactions by focusing on the central role of two chemokines, CX3CL1 (fractalkine) and CCL2 (MCP-1), because they differentially regulate neuronal-glial interactions. Release of CX3CL1 from neurons is ideal to mediate neuronal-to-microglial signaling, since the sole receptor of this chemokine, CX3CR1, is expressed in spinal microglia and activation of the receptor leads to phosphorylation of p38 MAP kinase in microglia. Although CCL2 was implicated in neuronal-to-microglial signaling, a recent study shows a novel role of CCL2 in astroglial-to-neuronal signaling after nerve injury. In particular, CCL2 rapidly induces central sensitization by increasing the activity of NMDA receptors in dorsal horn neurons. Insights into the role of chemokines in neuronal-glial interactions after nerve injury will identify new targets for therapeutic intervention of neuropathic pain.
Gao
Yong-Jing
YJ
Pain Research Center, Department of Anesthesiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States. yjing@zeus.bwh.harvard.edu
Ji
Ru-Rong
RR
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000073883:CX3C Chemokine Receptor 1; D002490:Central Nervous System / Q000378:metabolism*; D018932:Chemokine CCL2 / Q000378:metabolism*; D054428:Chemokine CX3CL1 / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D008959:Models, Neurological; D009410:Nerve Degeneration / Q000378:metabolism; D009437:Neuralgia / Q000188:drug therapy / Q000378:metabolism*; D009457:Neuroglia / Q000378:metabolism*; D009473:Neuronal Plasticity; D009474:Neurons / Q000378:metabolism*; D018121:Receptors, Cytokine / Q000378:metabolism; D015728:Receptors, HIV / Q000378:metabolism
D000700:Analgesics; D000073883:CX3C Chemokine Receptor 1; D018932:Chemokine CCL2; D054428:Chemokine CX3CL1; D018121:Receptors, Cytokine; D015728:Receptors, HIV